The Senate Parliamentarian reversed course on a small provision in the One Big Beautiful Bill Act that could boost cures for ...

Will the U.S. government adopt price controls on prescription drugs? If so, what would they look like? Seeking Alpha analysts ...

Expansion of the Medicare drug price negotiation rare disease drug carve-out would unnecessarily limit the number of drugs ...

President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy. But will ...

The Orphan Cures Act has been added back into the Senate version of President Donald Trump’s “big, beautiful bill” after being ...

In his first term, Trump made a lot of noise about lowering drug prices but accomplished little of consequence. The noise continues, but it is now accompanied by new ill-conceived initiatives, ...

The pharmaceutical industry’s lobbying muscle scored a high-stakes victory on Monday when the Senate parliamentarian reversed a previous decision and ruled that the Optimizing Research Progress Hope ...

The bill would cut $1.1 trillion in health-care spending and result in 11.8 million people losing health coverage over the ...

The Senate passed its version of the GOP megabill on Tuesday, and big players across the health care industry have been quick ...

Trump and Elon Musk have also spread unsubstantiated claims about rampant “waste, fraud, and abuse ” within the SSA, and they ...

Ted Okon, MBA, of the Community Oncology Alliance discusses how community oncology faces a revenue crisis due to the ...

Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...